US66987V1098
US66987V1098
Novartis AG
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 273.23B EUR | 297.88B EUR | 291.46B EUR | 263.08B EUR |
Enterprise Value | 313.81B EUR | 339.28B EUR | 331.58B EUR | 287.02B EUR |
Valuation Multiples | ||||
Trailing P/E | 21.71x | 23.35x | 21.54x | 25.35x |
Forward P/E | 14.68x | -- | -- | -- |
Price to Sales | 4.82x | 5.25x | 5.15x | 6.11x |
Price to Book | 6.58x | 7.17x | 7.57x | 5.7x |
EV/Revenue | 5.54x | 5.98x | 5.86x | 6.67x |
EV/EBITDA | 13.59x | 15.11x | 14.8x | 16.89x |
Price to FCF (P/FCF) | 22.96x | 19.89x | 18.26x | 20.09x |
EV/FCF | 26.37x | 22.65x | 20.77x | 21.92x |
FCF Yield | 4.36% | 5.03% | 5.48% | 4.98% |